The AACR Cancer Policy Monitor is your monthly source for policy news that impacts cancer research.
Application Deadline: Dec. 3
Learn how the AACR reviews Dream Team proposals to identify the most promising ideas.
Long-term Survival Rate for Subset of Patients With Advanced Melanoma Following BRAF- and MEK-targeted Treatment Combination Higher Than Historical Rate
Antibody-Drug Conjugate Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
AACR Applauds Nomination of Stephen M. Hahn, MD, as FDA Commissioner
EACR-AACR Basic and Translational Research Conference
AACR-Bristol-Myers Squibb Midcareer Female Investigator Grant
AACR Gertrude B. Elion Cancer Research Award
Advancing Precision Medicine Drug Development